drugset

drugset / Trial / NCT00726427

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

NCT00726427 ↗

Phase 1 Completed 32 enrolled AstraZeneca

RandomizedFactorialSingle-blindTreatment

Summary

The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects

Timeline

Start: 2008-07
Primary completion: 2008-09
Completion: 2008-09

Publications

Ericsson H, Roshammar D, Wollbratt M, Heijer M, Persson M, Ueda S, Leonsson-Zachrisson M, Norjavaara E. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther. 2012 Nov;50(11):765-77. doi: 10.5414/CP201747.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1656	Small molecule	180 mg	Oral

Indications

No indication recorded.